Xoma Corporation

Manik Baltaian

Arnold H Horwitz

David J Burke

Lynn S Grinna

Georgia Theofan

Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. Also disclosed are DNA sequences encoding methods for the production of the same in appropriate host cells, and stable homogeneous pharmaceutical compositions containing the analogs suitable for use treatment of gram negative bacterial infection and its sequelae.

Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same

Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. Also disclosed are DNA sequences encoding methods for the production of the same in appropriate host cells, and state homogeneous pharmaceutical compositions containing the analogs suitable for use treatment of gram negative bacterial infection and in sequelae.

Stable bactericidal permeability-increasing protein products and pharmaceutical compositions containing the same

Stable bactericidal/permeability-increasing protein products and

Stable bactericidal/permeability-increasing protein muteins

Growing community of inventors

Glendale, CA, United States of America

Manik Baltaian